ArticleInternational journal of nanomedicine2017
Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles.
Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Decidualization-empowered ECM hydrogel integrating sustained Tβ4 release drives endometrial regeneration in intrauterine adhesions.Nature communications · 2026Article
- Rg1-Loaded Tetrahedral DNA Nanostructures Attenuate Myocardial Ischemia-Reperfusion Injury by Suppressing Oxidative and Endoplasmic Reticulum Stress.International journal of nanomedicine · 2026Article
- The Emergence of Nanotechnology in the Prognosis and Treatment of Myocardial Infarctions.Recent patents on nanotechnology · 2025Review
- Tailoring Treatment in Cardiovascular Diseases: The Role of Targeted Therapies.Pharmaceutics · 2024Review
- Review
- Advanced Nanomedicine Approaches for Myocardial Infarction Treatment.International journal of nanomedicine · 2024Review
- Recent advances of CREKA peptide-based nanoplatforms in biomedical applications.Journal of nanobiotechnology · 2023Review
- Nanoparticle Based Cardiac Specific Drug Delivery.Biology · 2023Review
- Small non-coding RNA therapeutics for cardiovascular disease.European heart journal · 2022Review
- Dendritic Self-assembled Structures from Therapeutic Charged Pentapeptides.Langmuir : the ACS journal of surfaces and colloids · 2022Article
- Polymeric nanoparticles in the diagnosis and treatment of myocardial infarction: Challenges and future prospects.Materials today. Bio · 2022Review
- Non-Viral Gene Delivery Systems for Treatment of Myocardial Infarction: Targeting Strategies and Cardiac Cell Modulation.Pharmaceutics · 2021Review
- Biologics and their delivery systems: Trends in myocardial infarction.Advanced drug delivery reviews · 2021Review
- Review
- Photoacoustic Imaging of Myocardial Infarction Region Using Non-Invasive Fibrin-Targeted Nanoparticles in a Rat Myocardial Ischemia-Reperfusion Model.International journal of nanomedicine · 2021Article
- Review
- Nanoparticles: Promising Tools for the Treatment and Prevention of Myocardial Infarction.International journal of nanomedicine · 2021Review
- Nanostructured Polymeric, Liposomal and Other Materials to Control the Drug Delivery for Cardiovascular Diseases.Pharmaceutics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThymosin beta 4 (Tβ4) has multiple beneficial facets for myocardial injury, but its efficiency is limited by the low local concentration within the infarct. Here, we established a Tβ4 delivery system for cardiac repair based on the interaction between the abundant fibrin in the infarct zone and the fibrin-targeting moiety clot-binding peptide cysteine-arginine-glutamic acid-lysine-alanine (CREKA). METHODS AND
resultsCREKA and Tβ4 were conjugated to nanoparticles (CNP-Tβ4). In vitro binding test revealed that CNP-Tβ4 had a significant binding ability to the surface of fibrin clots when compared to the control clots (NP-Tβ4). Based on the validation of fibrin expression in the early stage of ischemia injury, CNP-Tβ4 was intravenously administered to mice with acute myocardial ischemia-reperfusion injury. CNP-Tβ4 revealed a stronger fibrin-targeting ability than the NP-Tβ4 group and accumulated mainly in the infarcted area and colocalized with fibrin. Subsequently, treatment with CNP-Tβ4 resulted in a better therapeutic effect.
conclusionCRKEA modification favored Tβ4 accumulation and retention in the infarcted region, leading to augmented functional benefits. Fibrin-targeting delivery system represents a generalizable platform technology for regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.